Rytmonorm 150 mg film-coated tablets

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Rytmonorm 150 mg coated tablets

Propafenone hydrochloride

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, since it could harm them.
• If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if these effects are not listed in this leaflet. See section 4.

Leaflet contents:

1. What Rytmonorm is and what it is used for

2. What you need to know before taking Rytmonorm

3. How to take Rytmonorm

4. Possible adverse effects

5. Storage of Rytmonorm

6. Contents of the container and other information

1. What Rytmonorm is and what it is used for

Rytmonorm is a medicine used to treat various types of cardiac arrhythmias. It belongs to a group of medicines called class 1C antiarrhythmics according to the Vaughan Williams classification.

Rytmonorm is used for the treatment and prevention of paroxysmal supraventricular tachycardia, including atrial fibrillation and paroxysmal flutter, as well as paroxysmal tachycardia due to re-entry phenomena involving the atrioventricular node or accessory pathways (Wolff-Parkinson-White syndrome). It is also indicated for the treatment and prevention of ventricular arrhythmias, including symptomatic ventricular extrasystoles and/or non-sustained and sustained ventricular tachycardia.

2. What you need to know before starting to take Rytmonorm

Do not take Rytmonorm

• If you are allergic to the active substance or to any of the other components of this medicine (listed in section 6).

• If you have a history of Brugada syndrome (a hereditary condition characterized by an abnormality in the electrocardiogram (ECG) and an increased risk of sudden death) (see Warnings and precautions).

• If you have had a myocardial infarction within the previous 3 months before starting treatment.

• If you have or have had significant heart disease such as:

  • congestive heart failure
  • cardiogenic shock unless caused by an arrhythmia
  • severe slowing of the heartbeat (bradycardia)
  • sinus node dysfunction, atrial conduction defects, second-degree or higher atrioventricular block, or bundle branch block or distal block, and you do not have an artificial pacemaker
  • if you have severe hypotension.

• If you have an electrolyte imbalance in the blood (e.g. disturbances in potassium metabolism).

• If you have severe obstructive pulmonary disease.

• If you have myasthenia gravis.

• If you are taking ritonavir (an antiretroviral used in the treatment of HIV infection, see Taking Rytmonorm with other medicines).

Warnings and precautions

Consult your doctor or pharmacist before starting to take Rytmonorm:

• It is essential that every patient receiving propafenone be clinically and electrocardiographically evaluated before and during treatment with Rytmonorm to determine whether the response to propafenone justifies continued treatment.
• After treatment with this medicine, your doctor must rule out Brugada syndrome, which may have been present without prior symptoms.
• If you have a pacemaker, because treatment may affect it, so it must be monitored and, if necessary, reprogrammed.
• If you have atrial fibrillation, because Rytmonorm may lead to the occurrence of a more serious arrhythmia; see Possible side effects.
• If you have severe heart disease, because you may be predisposed to serious adverse reactions, in which case treatment with this medicine is contraindicated.
• If you have asthma or another chronic obstructive respiratory disease.

Children

Interaction studies have only been conducted in adults, so it is unknown whether they are similar in children.

Elderly patients

Rytmonorm must be used with extreme caution in elderly patients.

Taking Rytmonorm with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicine.

More adverse effects may occur with Rytmonorm when administered together with local anesthetics (e.g. for pacemaker implantation, surgical or dental procedures), as well as with other drugs that have inhibitory effects on the heart such as beta-blockers (for hypertension) or certain antidepressants.

Inform your doctor if you are taking any of the following medicines, as they may increase their blood levels:

• venlafaxine (for depression)

• propranolol (for hypertension and angina pectoris)

• metoprolol (for hypertension)

• desipramine (for depression)

• cyclosporine (to suppress the body's immune defenses)

• theophylline (for asthma)

• digoxin (for heart problems)

If signs of overdose occur, the doses of these medicines should be reduced, as directed by your doctor.

Inform your doctor if you are taking any of the following medicines, as they may increase your blood levels of propafenone hydrochloride, so you may need to be monitored and have your dose adjusted:

• ketoconazole (for fungal infections)
• cimetidine (for stomach ulcers)
• quinidine (for heart arrhythmia or malaria)
• erythromycin (antibiotic)
• fluoxetine (for depression)
• paroxetine (for depression)

An increase in propafenone hydrochloride levels also occurs with grapefruit juice.

Concomitant use of Rytmonorm and amiodarone may cause heart disturbances. Dose adjustment of both medicines may be necessary.

The combined use of propafenone and lidocaine increases the risk of lidocaine's side effects on the central nervous system.

Inform your doctor if you are taking any of the following medicines, as they may reduce the effectiveness of Rytmonorm:

• rifampicin (antibiotic)
• phenobarbital (sedative and antiepileptic)
• phenytoin (antiepileptic)
• carbamazepine

In the case of chronic treatment with these medicines and Rytmonorm, the response to Rytmonorm treatment should be monitored.

Inform your doctor if you are taking medications to prevent blood clotting (e.g. acenocoumarol or warfarin), because Rytmonorm may enhance the effect of these medicines, increasing the risk of bleeding. It may be necessary to reduce the dose of the anticoagulant.

Taking Rytmonorm with food and drink

Due to the bitter taste and the superficial anesthetic effect of propafenone hydrochloride, Rytmonorm coated tablets must be taken without sucking or chewing, accompanied by liquid.

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

There are no adequate and well-controlled studies in pregnant women. Rytmonorm should not be used during pregnancy unless the expected benefit justifies the potential risk to the fetus. Propafenone hydrochloride crosses the placental barrier.

Excretion of propafenone hydrochloride in breast milk has not been studied. Limited data suggest that propafenone hydrochloride may pass into breast milk; therefore, it should be used with caution in breastfeeding mothers.

Driving and using machines

During treatment, blurred vision, dizziness, fatigue, or low blood pressure may occur; therefore, if you experience these symptoms, you should not drive or operate dangerous machinery.

Rytmonorm contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per coated tablet; hence, it is essentially "sodium-free".

3. How to take Rytmonorm

Follow exactly the instructions for administering this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist.

Rytmonorm is administered orally.

Adults

Your doctor will determine your individual maintenance dose by monitoring your heart, i.e., through several electrocardiographic and blood pressure checks (titration phase). For the titration phase and maintenance therapy, a total daily dose of 450 mg to 600 mg divided into two or three daily doses (1 tablet of Rytmonorm 150 mg three times a day or 1 tablet of Rytmonorm 300 mg twice a day) is recommended for patients weighing approximately 70 kg.

Sometimes it may be necessary to increase the daily dose to 900 mg (2 tablets of Rytmonorm 150 mg three times a day).

For patients weighing less than 70 kg, the daily dose should be appropriately reduced, starting with 150 mg twice daily. Dose increases should not be made until the patient has received treatment for 3–4 days.

If you are an elderly patient or have heart damage, Rytmonorm 150 mg, like other antiarrhythmics, will be administered with great care during the titration phase, starting with a dose of 150 mg once daily and gradually increasing. The maintenance dose for each individual must be calculated with monitoring of heart function and repeated blood pressure measurements (titration phase). Any required dose increase should not be made until after 5 to 8 days of treatment.

The same applies to maintenance therapy. Any necessary dose increase should not be made until after 5 to 8 days of treatment.

Hepatic and/or renal impairment

If you have liver or kidney problems, your doctor will start treatment with a dose of 150 mg once daily and adjust the dose according to your response to treatment.

Use in children and adolescents

In children, the average daily dose is 10 to 20 mg of propafenone hydrochloride per kilogram of body weight, divided into 3 to 4 daily doses during the initial dose titration phase and maintenance therapy.

Dose increases should not be made until the patient has received treatment for 3–4 days.

The maintenance dose must be individually calculated with monitoring of heart function and repeated blood pressure measurements (titration phase).

Your doctor will advise you on the duration of your treatment. Do not stop treatment prematurely, as even if you feel better, your condition could worsen or recur.

Remember to take your medicine. Take the tablets at the same time every day.

If you think that the effect of Rytmonorm is too strong or too weak, inform your doctor or pharmacist.

If you take more Rytmonorm than you should

If you take more than the prescribed dose, contact your doctor immediately so that medical care can be provided promptly. Serious symptoms may occur. If you have taken more Rytmonorm than prescribed, you may experience heart-related effects and low blood pressure, which in severe cases can lead to cardiovascular shock. Headache, dizziness, blurred vision, tingling or numbness of the skin, tremor, nausea, constipation, and dry mouth are often observed.

In severe intoxications, seizures, tingling or numbness of the skin, somnolence, coma, and respiratory arrest may occur. Fatal cases have been reported.

If this occurs, the patient must be monitored in an intensive care unit.

If you have taken more Rytmonorm than you should, consult your doctor or pharmacist immediately or call the Toxicology Information Service at 91.562.04.20, indicating the medicine and the amount ingested.

If you forget to take Rytmonorm

Do not take a double dose to make up for missed doses.

If you miss a dose, take the medicine as soon as possible and continue treatment as prescribed. However, if the next dose is due soon, it is better not to take the missed dose and wait for the next scheduled dose.

If you stop taking Rytmonorm

If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Adverse effects are classified as very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), and frequency not known (cannot be estimated from the available data).

Very common adverse reactions associated with propafenone treatment are dizziness, disturbances in cardiac conduction (heart abnormalities), and palpitations.

Within each category, adverse reactions are listed in descending order of severity, from most severe to least severe, when the severity for the patient could be determined.

The following adverse effects have been reported:

Blood and lymphatic system disorders:

• Uncommon: decrease in platelets (blood cells involved in clotting).
• Frequency not known: decrease in white blood cells (blood cells that defend the body against infections or foreign substances; may present as frequent infections with fever, chills, or sore throat), decrease in granulocytes (a type of white blood cell that may increase susceptibility to infections), severe reduction in granulocytes or neutrophils (agranulocytosis, a condition in which the person is more prone to infections).

Immune system disorders:

• Frequency not known: hypersensitivity¹.

¹ May manifest as cholestasis (arrest of bile flow to the duodenum), blood abnormalities, and skin rash.

Metabolism and nutrition disorders:

• Uncommon: decreased appetite.

Psychiatric disorders:

• Common: anxiety, sleep disorders.
• Uncommon: nightmares.
• Frequency not known: confusion.

Nervous system disorders:

• Very common: dizziness².
• Common: headache, altered taste perception.
• Uncommon: brief loss of consciousness (syncope), abnormal coordination, tingling sensation, numbness or pins-and-needles sensation in any part of the body, but most frequently in feet, hands, arms, or legs (paresthesia).
• Frequency not known: seizures, extrapyramidal symptoms (involuntary movements), restlessness.

² Excluding vertigo.

Eye disorders:

• Common: blurred vision.

Ear and labyrinth disorders:

• Uncommon: vertigo.

Cardiac disorders:

• Very common: disturbances in cardiac conduction³ (heart abnormalities), palpitations.
• Common: sinus bradycardia (slow heart rate), reduced heart rate (bradycardia), tachycardia (increased heart rate), atrial flutter (abnormal heart rhythm occurring in the cardiac atrium).
• Uncommon: ventricular tachycardia (increased heart rate originating in the ventricles, with more than 100 beats per minute), arrhythmia⁴ (abnormal heart rhythm that may increase, decrease, or become irregular).
• Frequency not known: ventricular fibrillation, heart failure⁵, reduced heart rate.

³ Including sinoatrial block, atrioventricular block, and intraventricular block.

⁴ Propafenone may be associated with proarrhythmic effects, manifesting as increased heart rate (tachycardia) or ventricular fibrillation. Some of these arrhythmias may be life-threatening and may require resuscitation to prevent potentially fatal outcomes.

⁵ Worsening of pre-existing heart failure may occur.

Vascular disorders:

• Uncommon: hypotension (decreased blood pressure).
• Frequency not known: hypotension after prolonged standing and/or upon standing (orthostatic hypotension).

Respiratory, thoracic and mediastinal disorders:

• Common: dyspnea (shortness of breath or difficulty breathing).

Gastrointestinal disorders:

• Common: abdominal pain, vomiting, nausea, diarrhea, constipation, dry mouth.
• Uncommon: abdominal distension (bloating), flatulence (gas).
• Frequency not known: retching, gastrointestinal discomfort.

Hepatobiliary disorders:

• Common: abnormal liver function.
• Frequency not known: liver injury, obstruction of bile flow from the liver (cholestasis), hepatitis, jaundice (yellowing of the skin and eyes).

Investigations:

• Common: abnormal liver function tests detected in blood tests, such as increased aspartate aminotransferase, increased alanine aminotransferase, increased gamma-glutamyl transferase, and increased alkaline phosphatase.

Skin and subcutaneous tissue disorders:

• Uncommon: urticaria, itching, skin rash, erythema (redness of the skin).

Musculoskeletal and connective tissue disorders:

• Frequency not known: lupus-like syndrome (an autoimmune disease).

Reproductive system and breast disorders:

• Uncommon: impotence (erectile dysfunction).
• Frequency not known: decreased sperm count⁷.

⁷ The reduction in sperm count is reversible upon discontinuation of propafenone.

General disorders and administration site conditions:

• Common: chest pain, asthenia (feeling of tiredness), fatigue, fever.

Reporting of adverse effects

If you experience any adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Rytmonorm

Keep this medicine out of sight and reach of children.

This medicine does not require any special storage conditions.

Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE Point at your pharmacy. Ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Rytmonorm

The active substance is propafenone hydrochloride. Each tablet contains 150 mg of propafenone hydrochloride.

The other components (excipients) are: microcrystalline cellulose, sodium croscarmellose, magnesium stearate, maize starch, hydroxypropylmethylcellulose, macrogol 400, macrogol 6000, titanium dioxide (E 171) and purified water.

Appearance of the product and contents of the pack

Rytmonorm 150 mg coated tablets are white, round tablets with "150" printed on one side.

Each pack contains 60 coated tablets.

Marketing Authorization Holder and Manufacturer

Holder:

Teva B.V.,

Swensweg 5,

2031GA Haarlem,

The Netherlands

Manufacturer:

ITC Production s.r.l.

Via Pontina km 29

00071 Pomezia (RM)

Italy

For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:

Teva Pharma, S.L.U.

C/ Anabel Segura, 11, Edificio Albatros B, 1ª planta

Alcobendas 28108 Madrid

Spain

Date of the most recent revision of this leaflet: March 2019

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

• ---

This information is intended for healthcare professionals only:

Management of overdose

In addition to general emergency measures, monitoring and correction of the patient's vital parameters (as necessary) must be performed in an intensive care unit.

Defibrillation as well as infusion of dopamine and isoprenaline have proven effective in controlling rhythm and blood pressure. Seizures have been relieved with intravenous diazepam. General supportive measures may be required, such as mechanical ventilation and external cardiac massage.

Attempts at elimination using hemoperfusion are poorly effective.

Hemodialysis has no effect due to the extensive protein binding of propafenone (> 95%) and its large volume of distribution.

Other presentations

Rytmonorm 300 mg coated tablets. Packages containing 60 coated tablets.

Rytmonorm 3.5 mg/ml injectable solution. Packages containing 5 vials of 20 ml.